• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis

tetano

Editor, Senior Moderator
J Cyst Fibros. 2011 Jul 11. [Epub ahead of print]
Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis.
Viviani L, Assael BM, Kerem E; The ECFS (A) H1N1 study group.
Source

Dipartimento di Medicina del Lavoro "Clinica del Lavoro L. Devoto", Sezione di Statistica Medica e Biometria "G.A.Maccacaro", Universit? degli Studi di Milano, Italy.
Abstract
BACKGROUND:

Influenza, like other respiratory viral infections, can cause acute deterioration of lung function in patients with cystic fibrosis (CF). Previous studies on a small number of patients reported that most people with CF infected with A (H1N1) influenza experienced a mild course of disease.
AIM:

To characterise the impact of A (H1N1) infection on CF in a large number of patients from different centres and countries.
METHODS:

CF centres accessing the web-site of the European Cystic Fibrosis Society (ECFS) were asked to report clinical data on patients with an ascertained diagnosis of influenza caused by the A (H1N1) virus. The study was web-based and data were collected through an electronic data sheet on the ECFS website.
RESULTS:

Twenty-five centres from 10 countries caring for 4698 patients with CF reported data on 110 patients (2.3%), median age 13years (range 1-39years). The prevalence of infection in each centre ranged from 0% to 9.4%. Only 8.8% of the patients had been vaccinated. The main symptoms were fever and respiratory exacerbation requiring IV antibiotics in 53% of the patients; 48% of the patients were hospitalised for an average of 12.9days (range 2-56) and 31% required oxygen treatment during the time of the infection. Most of the patients recovered and FEV(1) 1month after the infection was similar to that before the infection. However, 6 patients were admitted to ICU, 5 with mechanical ventilation. Three patients with severe respiratory disease died.
CONCLUSIONS:

A (H1N1) influenza infection caused transient but significant morbidity in most of the patients with CF. However, in a small number of patients with severe lung disease, A (H1N1) influenza was associated with respiratory deterioration, mechanical ventilation and even death.

Copyright ? 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

PMID:
21752728
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21752728
 
Back
Top Bottom